News

Zynex Laser Technology Revolutionizes Pulse Oximetry for All Skin Tones

Zynex Laser Technology Revolutionizes Pulse Oximetry for All Skin Tones

Zynex's Groundbreaking Study on Laser Pulse Oximetry

Zynex, Inc. (NASDAQ: ZYXI) is pioneering a new era in medical technology, particularly in the realm of pulse oximetry. This innovative company has shared remarkable insights from a recent study carried out at the University of California, San Francisco's (UCSF) Hypoxia Lab. The focus of the study was to compare the efficiency and accuracy of Zynex's NiCO™ laser pulse oximeter against conventional LED pulse oximeters, particularly in terms of how skin pigmentation affects SpO2 measurements.

The Challenge with Traditional LED Pulse Oximeters

Traditional LED pulse oximeters have long been known to pose challenges, particularly for individuals with darker skin tones. These devices estimate blood oxygen levels rather than directly measure them, leading to inaccuracies. Studies have indicated that these inaccuracies can result in higher false readings for individuals with dark pigmentation, especially when oxygen saturation levels are low. This often leads to disparities in care and raises critical concerns regarding patient safety and equity.

Highlighting the Study's Findings

The recent research involved participants of varying skin pigmentation—specifically, nine individuals with darker skin and nine with lighter skin. By using four NiCO pulse oximeters and two commercially available LED pulse oximeters, the researchers concluded that the NiCO device did not show bias toward any skin pigmentation. In contrast, the conventional LED devices significantly overestimated oxygen levels in darker-skinned individuals.

Implications for Racial Equity in Healthcare

Donald Gregg, President of Zynex Monitoring Solutions, emphasized the importance of these findings. He stated that the results not only confirm the accuracy of the NiCO pulse oximeter but also signify that it can help mitigate racial disparities in health care decisions. For example, the use of this technology could improve clinical judgment regarding the need for mechanical ventilation or supplementary oxygen, particularly for patients belonging to marginalized racial and ethnic groups.

Broader Context and Previous Research

This study adds to the compelling evidence from prior research done at Duke University, which highlighted similar accuracy in this laser-based technology. Furthermore, a 2022 Harvard Medical School study indicated that patients of color, including Black, Hispanic, and Asian patients, experienced discrepancies in care often due to inaccurate pulse oximeter readings, leading to inequitable health outcomes.

Looking Ahead: Zynex’s Commitment to Innovation

Zynex is optimistic about the evolving landscape of pulse oximetry with its laser technology. As they prepare their application for FDA clearance, the company is eager to share further developments that will continue to enhance patient care. The integration of advanced technology in medical devices like the NiCO pulse oximeter is poised to revolutionize how healthcare providers administer treatment and monitor patient health.

The Future of Pulse Oximetry in Clinical Settings

With a concerted focus on accuracy and patient-centered care, Zynex is determined to lead the charge towards closing healthcare gaps related to racial disparities. The increasing validation of laser technology in pulse oximetry signifies a potential shift towards a more equitable healthcare system, where all patients receive the care they deserve, irrespective of skin pigmentation.

About Zynex, Inc.

Zynex, founded in 1996, is dedicated to the development and marketing of medical devices aimed at enhancing patient outcomes, particularly in pain management and rehabilitation. Their innovative solutions also encompass non-invasive monitoring systems, including fluid, sepsis, and laser-based pulse oximetry technologies, tailored for hospital environments. To learn more about Zynex and their dedication to innovation, you can visit their website.

Frequently Asked Questions

What is the NiCO laser pulse oximeter?

The NiCO laser pulse oximeter is a device developed by Zynex that measures blood oxygen levels with high precision, reducing bias related to skin pigmentation.

How does the NiCO pulse oximeter differ from traditional devices?

Unlike traditional LED pulse oximeters that estimate oxygen levels, the NiCO provides direct measurements, which enhance accuracy across all skin tones.

Why is the study significant?

The results demonstrate that the NiCO pulse oximeter can help eliminate racial disparities in medical assessments, ensuring equitable care for all patients.

What future developments can we expect from Zynex?

Zynex is currently working towards FDA clearance and plans further advancements in their pulse oximetry technology to improve patient outcomes.

How does Zynex contribute to medical technology?

Zynex focuses on innovative medical solutions that prioritize patient safety and enhance treatment effectiveness, aiming to transform how care is delivered in medical settings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 283

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 240

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 243

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 235

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 205

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 251

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Community in Shock After Fatal Bakersfield Shooting

Updated Category News Views 164

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 606

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 322

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 205

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Electric Vehicle Production with Smart Technology

Updated Category News Views 153

Rockwell Automation Enhances Lucid's EV Manufacturing Rockwell Automation, Inc. (NYSE: ROK), renowned for its commitment to industrial automation and digital transformation, is set to significantly enhance the electric vehicle (EV) production capabilities for Lucid. This collaboration aligns with Saudi Arabia's Vision 2030, aiming to develop a sustainable and diversified...

Continue Reading
TeraWulf Inc. Seeks Growth with Convertible Notes and Google Deal

Updated Category News Views 158

TeraWulf Stock Overview TeraWulf Inc. (NASDAQ: WULF) is observing fluctuations in its stock value amidst significant financial developments. The company's stock experienced a minor drop of 0.96%, settling at $9.29 in pre-market trading. Investors are closely monitoring the implications of recent announcements on the company's future Convertible Notes Offering Details...

Continue Reading
Kaltura's Growth Prospects and Strategic Insights Explored

Updated Category News Views 301

Kaltura got analysts buzzing back in 2024 with their second-quarter results that had the desks reeling. Adjusted EBITDA hit $1.6 million when everyone was just hoping for $0.2 million. Revenue? $44 million, up from the expected $43.1 million—these numbers showed Kaltura wasn’t just treading water; they were swimming against the tide. Kaltura's Performance Metrics: A...

Continue Reading
Nvidia's Unprecedented Market Influence in the AI Era

Updated Category News Views 139

Nvidia's Rise as a Technological Powerhouse Nvidia Corporation (NASDAQ: NVDA) has reached a new peak in its market valuation, crossing a staggering $4 trillion. Investors have welcomed the recent news regarding the resumption of sales of its advanced AI chips, boosting trust in the company's future prospects. This surge heightens interest in Nvidia, showcasing a potential...

Continue Reading
Global Oil Prices Drop Amid Trade Tensions and Demand Concerns

Updated Category News Views 392

Oil Prices Facing Declines Recent trends indicate that oil prices have been on a downward trajectory, particularly influenced by uncertainties surrounding geopolitical tensions and tariffs imposed by the U.S. However, a critical observation is that these factors intertwine to significantly affect global economic conditions and energy demand. Current Status of Oil Pricing...

Continue Reading